Entrada Therapeutics, Inc. Common Stock (TRDA)
Entrada Therapeutics, Inc. is a biotechnology company focused on developing intracellular biologic therapies. Utilizing its proprietary platform, the company aims to create innovative treatments for diseases with high unmet medical needs by delivering therapeutic molecules directly into cells.
Company News
Entrada Therapeutics awarded $50,000 grants to Jett Foundation and Parent Project aps to support Duchenne muscular dystrophy community initiatives focused on equity, accessibility, and inclusion in the U.S. and Italy.
Entrada Therapeutics reported a significant revenue drop and wider-than-expected loss in Q2 2025, primarily due to the conclusion of its partnership with Vertex Pharmaceuticals. Despite financial challenges, the company continues advancing its clinical pipeline for neuromuscular and genetic disease therapies.
Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for ...